Renee Aguiar Lucander

About Renee Aguiar Lucander

Renée Aguiar-Lucander is an international life sciences executive known for her expertise in strategy, financing, and the scaling of biopharmaceutical companies. Since April 2025, she has served as CEO of Hansa Biopharma. She also joined Inventiva’s Board of Directors in 2025, following shareholder approval, bringing a high-value profile to a company that is advancing through a critical clinical and strategic phase. Inventiva has highlighted her track record as particularly relevant as the company prepares for late-stage development and the potential future commercialization of its lead program. Before Hansa Biopharma, Aguiar-Lucander was CEO of Calliditas Therapeutics. In that role, she led the company’s transformation from a small biotech into a Nasdaq-listed, commercial-stage rare disease company. Under her leadership, Calliditas secured the first FDA approval for a treatment for IgA nephropathy, TARPEYO®, and successfully launched the product in the U.S. She also oversaw the strategic journey that ultimately led to Calliditas’ acquisition by Asahi Kasei in 2024 for approximately $1.1 billion, underscoring her ability to build value and execute across the full company life cycle. Her earlier career combined investment, corporate finance, and healthcare exposure. She held senior roles as Partner and COO at Omega Fund Management and also worked in senior positions at a global investment bank. That mix of financial discipline and operational leadership is especially valuable in biotech, where capital allocation, clinical execution, investor communication, and regulatory milestones are all tightly linked. Aguiar-Lucander holds an MBA from INSEAD and a B.A. in Finance from the Stockholm School of Economics. She has built a reputation as a board-level and C-suite leader who can support innovative companies in demanding environments. At Inventiva, her experience in public markets, growth financing, rare disease commercialization, and governance adds meaningful strength to the company’s board as it advances its strategic priorities.